Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2012; 18(8): 821-832
Published online Feb 28, 2012. doi: 10.3748/wjg.v18.i8.821
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart showing the abstract screening and study selection process. CBM: Chinese BioMedical Literature on disc; CMCC: Chinese Medical Current Contents; CNKI: Chinese National Knowledge Infrastructure.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Gender difference in trials. M-H: Mantel-Haenszel.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Proteinuria change in steroid combination therapy. IV: Inverse variance.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Serum albumin change in combination therapy group. IV: Inverse variance.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Alanine aminotransferase change in combination therapy group. IV: Inverse variance.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Scr change in combination therapy group. IV: Inverse variance.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 Hepatitis B virus-DNA titer change in combination therapy group. IV: Inverse variance.
Figure 8
Open in New Tab Full Size Figure Download Figure
Figure 8 Proteinuria remission rate in different dose glucorticosteroids subgroups. IV: Inverse variance.
Figure 9
Open in New Tab Full Size Figure Download Figure
Figure 9 Proteinuria remission rate in membranous glomerulonephritis and mesangial proliferative glomerulonephritis subgroups. M-H: Mantel-Haenszel; MN: Membranous glomerulonephritis; MsPGN: Mesangial proliferative glomemlonephrits; CR: Complete remission; R: Remission.
Figure 10
Open in New Tab Full Size Figure Download Figure
Figure 10 Proteinuria remission rate in membranous glomerulonephritis and membranoproliferative glomerulonephritis subgroups. M-H: Mantel-Haenszel; MN: Membranous glomerulonephritis; MPGN: Membranoproliferative glomerulonephritis; CR: Complete remission; R: Remission.
Figure 11
Open in New Tab Full Size Figure Download Figure
Figure 11 Risk of bias graph: Review authors' judgments about each risk of bias item presented as percentages across all included studies.
Figure 12
Open in New Tab Full Size Figure Download Figure
Figure 12 Risk of bias graph: Review authors' judgments about each risk of bias item for each included study.
Figure 13
Open in New Tab Full Size Figure Download Figure
Figure 13 Publication bias analysis. A: Funnel plots of proteinuria treatment with steroid combination therapy; B: Funnel plots of serum albumin change with steroid combination therapy; C: Funnel plots of proteinuria change under different combined glucorticosteroids drugs; D: Funnel plots of remission rate vs complete remission rate of MN and MsPGN groups; E: Funnel plots of remission rate vs complete remission rate of MN and MsPGN groups. MN: Membranous glomerulonephritis; MsPGN: Mesangial proliferative glomemlonephrits; R: Remission; CR: Complete remission; RR: Relative risk; MD: Mean difference.